Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an Anti-Inflammatory diet designed for Crohn's disease also tame IBS?

NCT ID NCT07707635

Not yet recruiting Disease control Sponsor: Ariel University Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether a modified version of the Crohn's Disease Exclusion Diet (CDED) can ease symptoms of non-constipation irritable bowel syndrome (IBS) better than the standard low FODMAP diet. About 150 adults with moderate-to-severe IBS will follow one of the two diets for six weeks. Researchers will track symptom changes, gut inflammation, and microbiome health to see if the CDED offers added benefits beyond symptom relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a modified Crohn's Disease Exclusion Diet (CDED) adapted for IBS, excluding the enteral formula
What this could lead to
If effective, the modified CDED could offer a new dietary option for people with IBS that targets inflammation and gut health, potentially improving symptoms and quality of life.
What could go wrong
This is a relatively small, early-stage study, and the modified CDED may not prove superior to the standard low FODMAP diet. Dietary interventions can be hard to follow, and results may not apply to everyone with IBS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IRRITABLE BOWEL SYNDROME (IBS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alpha 1-antitrypsin deficiency irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IRRITABLE BOWEL SYNDROME (IBS)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.